Strata Critical Medical (Nasdaq: SRTA) Delivers Strong Q4 2025 Results and Raises 2026 Outlook

Key Highlights from the Report

• Q4 2025 revenue reached \$197.1 million and Adjusted EBITDA hit \$14.1 million—both surpassing the high end of company guidance.
• Full-year 2026 guidance raised: Revenue now expected in the range of \$260 million to \$275 million (previously \$255–\$270 million); Adjusted EBITDA projected at \$29 million to \$33 million (up from \$26–\$31 million).
• Company remains listed on the Nasdaq, trading under the ticker symbols SRTA (Common Stock) and SRTAW (Warrants).
• Cash and cash equivalents at year-end 2025 were \$19.8 million; short-term investments totaled \$30.3 million.
• No preferred stock outstanding. 86.7 million common shares issued as of December 31, 2025.
• Net loss for the full year 2025 was \$(27.3) million, reflecting ongoing investments in growth and strategic initiatives.
• Gross margin for Q4 2025 was 21.6%.
• Adjusted EBITDA margin for Q4 2025 was 13.4%.

Details Investors Should Know

Fourth Quarter and Full-Year 2025 Financials

• Q4 2025 Revenue: \$66.8 million (up from \$45.9 million in Q4 2024).
• Full-Year 2025 Revenue: \$197.1 million (up from \$146.8 million in 2024, a 34% increase).
• Q4 2025 Gross Profit: \$14.4 million (up from \$8.8 million in Q4 2024).
• Full-Year 2025 Gross Profit: \$41.1 million (up from \$29.6 million in 2024).
• Q4 2025 Adjusted EBITDA: \$7.0 million (up from \$1.1 million in Q4 2024, a 547% increase).
• Full-Year 2025 Adjusted EBITDA: \$13.8 million (up from \$3.7 million in 2024).
• Operating Expenses: Selling, general, and administrative (SG&A) expenses were \$19.3 million in Q4 2025 (versus \$13.2 million in Q4 2024), totaling \$60.9 million for the year (up from \$50.9 million in 2024).
• Net Loss: \$(8.8) million in Q4 2025 and \$(27.3) million for the year, compared to net losses of \$(15.8) million and \$(53.4) million in the prior year periods.

Balance Sheet Strength

• Total Assets: \$325.5 million as of December 31, 2025 (up from \$254.5 million a year prior).
• Total Stockholders’ Equity: \$279.1 million at year-end 2025 (up from \$221.9 million in 2024).
• No preferred stock outstanding.
• Goodwill and intangibles: Goodwill at \$88.2 million, intangible assets at \$47.5 million, reflecting strategic investments and acquisitions.

2026 Outlook Revised Upward

• Revenue now expected between \$260 million and \$275 million (previously \$255–\$270 million).
• Adjusted EBITDA guidance raised to \$29–\$33 million (previously \$26–\$31 million).
• The company notes it is not able to reconcile Adjusted EBITDA guidance to GAAP net income due to variability in certain items, including stock-based compensation and transaction-related expenses.

Potential Price-Sensitive Information

• Raising guidance for both revenue and Adjusted EBITDA is likely to be viewed positively by the market and may have a share price impact.
• The company’s strong Q4 results, with both revenue and Adjusted EBITDA at the high end of prior guidance, suggest continued operational momentum.
• Substantial year-over-year growth in revenues (34%) and significant improvement in Adjusted EBITDA (up 274% for the year) indicate effective execution on strategic initiatives.
• Net loss remains, but is narrowing; investments in SG&A and growth are ongoing.
• Healthy cash and investment balances support ongoing operations and growth initiatives.

Other Notable Information

• The company will host a conference call to discuss results on March 3, 2026, at 8:00 a.m. ET. A webcast replay will be available on the investor relations website for one year.
• No preferred stock is outstanding; 86.7 million common shares issued as of year-end 2025.

Summary Table: Key Financials

Conclusion

Strata Critical Medical’s fourth quarter and full-year 2025 results demonstrate robust operational execution, with strong year-over-year growth in both revenue and profitability metrics. The upward revision to 2026 guidance is likely to be viewed very positively by investors, signaling management’s confidence in the company’s growth trajectory. While the company remains in a net loss position, improving margins, strong cash balances, and strategic investments position Strata for continued progress. The upcoming investor call may provide further color on the company’s market outlook and strategic initiatives.

Disclaimer: This summary is provided for informational purposes only and does not constitute investment advice. Investors should review the company’s full filings and consult with a financial advisor before making any investment decisions. The information above is based on the company’s press release and reported financial statements as of March 3, 2026.

View Strata Critical Medical, Inc. Historical chart here